Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Wire Texas.
Press releases published on August 29, 2025
Bicycle Toxin Conjugates Clinical Trials FDA Approval Proprietary Technology Cancer Drugs Report 2025
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Bicycle Toxin Conjugates Clinical Trials, Proprietary Platforms …
RNA Polymerase I POL 1 Clinical Trials Companies FDA Approval Development Trends Report 2025
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global RNA Polymerase I Clinical Trials, Development Trends By Indications, Target Approaches …
Tetraspecific Antibodies Clinical Trials FDA Approval Development Technologies Platforms Market Opportunity Companies Report 2025
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Tetraspecific Antibodies Clinical Trials, Proprietary Technologies, Therapeutic Approaches …
Bispecific Antibody Drug Conjugates ADC Clinical Trials FDA Approval Companies Commercial Launch Report 2025
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Drug Conjugates Clinical Trials, Development Platforms, Competitive Landscape and Market Opportunity Insight 2025 Report Findings and Highlights: First Bispecific Antibody Drug Conjugate …
Controlled Release Drug Delivery Market Size FDA Approved Drugs Clinical Trials Companies Report 2030
GlobeNewswire
·
August 29, 2025
Delhi, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Global Controlled Release Drug Delivery Market, Drug Dosage, Price, Sales and Clinical Trials Insight 2030 Report Finding and Highlights: Research Methodology Followed Global and Regional Market Overview Global …
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
GlobeNewswire
·
August 29, 2025
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM Nantes, August 29, 2025, 8:00 a.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today published a comprehensive …
OSE Immunotherapeutics Réaffirme ses Priorités Stratégiques et Publie un Document Questions-Réponses Destiné aux Actionnaires pour Rétablir l’Information Avant l’Assemblée Générale
GlobeNewswire
·
August 29, 2025
OSE Immunotherapeutics Réaffirme ses Priorités Stratégiques et Publie un Document Questions-Réponses Destiné aux Actionnaires pour Rétablir l’Information Avant l’Assemblée Générale NANTES, France - 29 août 2025, 8h00 CET – OSE Immunotherapeutics SA (ISIN: …
Santhera schliesst Vereinbarung mit Ikris Pharma Network über den Vertrieb von AGAMREE® (Vamorolon) in Indien
GlobeNewswire
·
August 29, 2025
Pratteln, Schweiz, 29. August 2025 – Santhera Pharmaceuticals (SIX: SANN) gibt die Unterzeichnung einer exklusiven Vereinbarung mit Ikris Pharma Network (Ikris) über den Vertrieb von AGAMREE® (Vamorolon) in Indien zur Behandlung von Duchenne- …
Santhera Enters into Agreement with Ikris Pharma Network for the Distribution of AGAMREE® (Vamorolone) in India
GlobeNewswire
·
August 29, 2025
Pratteln, Switzerland, 29 August, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAMREE® (vamorolone) in India, for the treatment of Duchenne …
Banner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®
GlobeNewswire
·
August 29, 2025
NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025. …